"During the last two years, we have solidified our position in the orphan disease space and made significant progress in bringing life-changing medicines to people with urea cycle disorders," Hyperion CEO Donald Santel said in a prepared statement Monday.
Date: Mar 30, 2015
Source: Google
Hyperion Therapeutics to acquire Andromeda Biotech – Quick Facts
Donald Santel, president and chief executive officer of Hyperion, said, ''The acquisition of Andromeda Biotech is a transformative event for Hyperion. We believe DiaPep277 has the potential to become a highly differentiated, first-in-class medicine for an orphan indication with a significant unmet n